Skin and Connective Tissue Diseases Clinical Trial
Official title:
Skin Irritation Test of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects
Verified date | February 2015 |
Source | LEO Pharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | Japan: Pharmaceuticals and Medical Devices Agency |
Study type | Interventional |
The purpose of the study is to investigate skin irritation of LEO 80185 gel, gel vehicle and Liquid Paraffin in healthy Japanese male subjects.
Status | Completed |
Enrollment | 33 |
Est. completion date | April 2015 |
Est. primary completion date | April 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 20 Years to 40 Years |
Eligibility |
Inclusion Criteria: 1. Signed informed consent has been obtained. 2. Healthy Japanese male subjects. 3. Aged 20 to 40 years inclusive. 4. Subjects without signs of skin irritation/disease/disorders/symptoms or blemishes on test sites (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn). 5. Subjects without a significant abnormality, as judged by the (sub)investigator Exclusion Criteria: 1. Body Mass Index outside the range 18-25 kg/m² 2. History of alcohol or drug abuse. 3. History of allergic reaction to any medications. 4. Any disease that could in any way confound assessment of the test sites. 5. Known or suspected hypersensitivity to any component of LEO 80185 gel. 6. Known or suspected hepatic, renal or cardiac disorders. 7. Known or suspected disorders of calcium metabolism associated with hypercalcaemia or albumin-corrected serum calcium above the reference range from the sample taken during screening. 8. Subjects suspected of infection based on the infection testing results from the sample taken during screening (Hepatitis B surface antigen, HCV antibody, HIV antigen/antibody, serological test for syphilis). 9. Use of systemic, locally injected or inhaled corticosteroids within 4 weeks of Day 1. 10. Use of vitamin D or calcium supplements, or systemic vitamin D analogues within 4 weeks of Day 1. 11. Use of any medication (systemic or topical) within 2 weeks of Day 1. 12. Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within 4 weeks or 5 half-lives of Day 1, whichever is longest. 13. Current participation in any other interventional clinical trial. 14. Previously enrolled in this clinical trial. 15. Previous or current photo-induced or photo-aggravated disease (e.g. abnormal response to sunlight). 16. Exposure to excessive or chronic ultraviolet radiation (e.g. sunlight, sun lamps, tanning booths or photo-therapy) within 4 weeks of Day 1. 17. Subjects (or their partner) not using an adequate method of contraception during the trial (Day 1-4). 18. In the opinion of the (sub)investigator, participation in the trial is inappropriate. |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Japan | Medical Co. LTA HAKATA Clinic | Random Square 5F, 6-18 Tenyamachi, Hakata-ku | Fukuoka |
Lead Sponsor | Collaborator |
---|---|
LEO Pharma |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Skin irritation measured as -, +/-, +, ++, +++, ++++ | 4 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04971200 -
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
|
Early Phase 1 | |
Active, not recruiting |
NCT05525741 -
Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients
|
N/A | |
Completed |
NCT01093911 -
Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Completed |
NCT00147511 -
Time To Efficacy and Onset Of Action Of Linezolid
|
Phase 4 | |
Completed |
NCT02355639 -
A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin
|
Phase 1 | |
Completed |
NCT01764594 -
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
|
Phase 1 | |
Active, not recruiting |
NCT05185258 -
Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
|
Phase 4 | |
Completed |
NCT02985437 -
Safety and Tolerability of Topically Applied Bovine Lung Surfactant on Intact Skin
|
Phase 1 | |
Not yet recruiting |
NCT06427889 -
Treatment Effects of Two Pharmaceutical Skin Care Creams for Xerotic Feet Among Persons With Diabetes
|
Phase 4 | |
Completed |
NCT02518048 -
A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris
|
Phase 2 | |
Withdrawn |
NCT03196115 -
Biomarker for Hyaline Fibromatosis Syndrome (BioHFS)
|
||
Completed |
NCT02416258 -
A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)
|
Phase 2 |